

Index

a

- Abraxane 17
- absorption, distribution,
 - metabolism and excretion (ADME) 35, 36, 62, 72, 264
- academics
 - acyclic nucleoside phosphonates 29–31
 - anti-cancer drugs 12–20
 - antibiotics 11
 - artemisinin and artemether 20–21
 - biologic drugs 23–27
 - carfilzomib 21–23
 - darunavir 31–32
 - histone deacetylase inhibitors 27–29
 - monoclonal anti-CD20 antibody 5
 - patent lifetime 4
 - pregabalin 8–10
 - rituximab 5
 - sunitinib 32–33
 - thalidomide derivatives 5, 6
- activated partial thromboplastin time (APTT) 226–227, 230, 235–236
- activated Protein C (aPC)-catalyzed FVa inactivation 225
- activated prothrombin complex concentrate (aPCC) 224, 239–240, 242
- active pharmaceutical ingredients (API) 117
- acyclic nucleoside phosphonates 29–31
- adoptive cell transfer 160–161
- alanine scanning 91–92
- albiglutide 100
 - and albenatide 100
- alglucerase 26–27
- amino acid replacements 234
- 4-aminobutyrate-oxo-glutarate aminotransferase 8
- angiogenesis 6, 199
- annualized bleeding rates (ABRs) 236–237, 239–241
- α -anomer 130
- anti-cancer drugs
 - camptothecin 12–14
 - epothilones 17–18
 - eribulin 18–20
 - Taxol 14–17
- anti-drug (emicizumab) antibodies (ADAs) 236, 241–242
- antibiotics 11–12, 34
- antigen presenting cells (APCs) 162–165

antihyperglycemic agents 111,
136–137
antihyperglycemic drugs 111, 113,
115
aromatic amine analogs 254
artemether 20–21
artemisinin 20–21
aryl C-glucoside 114, 125
7-azabenzimidazole 277
azeotropic distillation 117

b

benzimidazole 277
o-Cl benzaldehyde 261
p-benzophenone 116
o-benzylphenol aglycones
114–115
bexagliflozin 114, 122–123,
136–137, 140, 142
biologic drugs
 alglucerase 26–27
 insulin 23–25
 rituximab 25–26
biomarkers 172–173, 226, 235
boron trifluoride etherate
116–117, 119, 121, 122, 125,
127–128, 131
bortezomib 22, 23, 48
breast cancer 18, 20, 160, 273–285
5-bromo-2-chloro analog 120
5-bromo-2-chlorobenzoic acid 115
4-bromo-1-chloro-2-[(4-ethoxy-
phenyl)methyl]benzene 117
2-bromoisonicotinonitrile 261
N-bromosuccinimide 128

c

C-terminus biphenyl alanine 102
calcitonin gene-related peptide
(CGRP) 209

alpha-CGRP 199
beta-CGRP 199
gut, role of 203
indications 211–212
migraine treatment
 allodynia 204
 central and peripheral nervous
 systems 203
 clinical correlation 203
 inflammatory cascade 203
 large molecule antagonists
 208–211
 neuronal plasticity and synapse
 formation 204
 polymodal nociceptors
 204–208
 small molecule antagonists
 204
 systemic circulation and levels
 200
 trigeminal nucleus caudalis
 (TNC) 203
neuropeptide 199
physiological role 200–202
small molecule CGRP-RA 207
camptothecin 12–14
canagliflozin 111, 125, 129–133,
137–139, 141–143
Cannizzaro reaction 129
capsaicin 200, 203
CAR T cells
 antigen recognition and response
 166
 approved therapies 186–187
 biomarkers of 172–173
 cancer therapy 179
 clinical trials 181–182
 cytokine release syndrome
 173–174
FDA approval 169

- first generation CARs 167
- human clinical trial 161–162
- licensing strategy 184
- long-lasting memory response 167–168
- neurotoxicity 174–175
- “on-target, off-tumor” toxicity 175–176
- pharmacokinetic profiles
 - expansion 170–171
 - persistence 171–172
 - trafficking 172
- pre-registration therapies 187–188
- production issues 176–179
- quality assurance (QA) unit 184
- quality control release testing 183
- retrospective analysis 185
- therapeutic application 167, 169
- therapeutic resistance 179–182
- carbon-linked heterocycles 254
- carfilzomib 21–23, 48
- CART19 cells 170–175, 180, 184, 188
- CDK4/6 inhibitors 273–285
- Ceredase™ 27
- chemotherapy 6–8, 12–13, 16, 187
- chimeric antigen receptor (CAR) 166, 175–176, 180, 183
 - design and evolution 168
- coagulation system 236
- combination treatments 282–283, 285
- complementarity-determining region (CDR) 161, 163, 234
- computer assisted methods 3
- CREDENCE trial 139
- cross-coupling reaction 131
- cryo electron microscopy (EM) 91
- cutaneous T-cell lymphoma (CTCL) 29
- cyclin-dependent kinases (CDKs) 273–274, 276, 278–279
- cyclosporine 64
- cytokine release syndrome 161, 173–174
- cytosolic 50
- d**
 - dapagliflozin 111, 114–117, 121, 125, 129, 136–144
 - darunavir 31–32
 - De Clercq, Erik 29–30, 35
 - DECLARE-TIMI 58 trial 137, 140–142
 - Degraders 47–71, 284
 - polar surface area (PSA) and partition coefficient 50
 - dienone-yne substrate 127
 - 3,3-difluorocyclobutan-1-amine hydrochloride 260–261
 - dihydroisobenzofuran moiety 127
 - dimethylamide 278, 280
 - 4,4-dimethyltetrahydrofuran ring 121
 - dipeptidyl peptidase-IV (DPP-IV) 90–91, 141
 - 2,*N*-diphenyl glycine inhibitor 251
 - 2,*N*-diphenyl glycine scaffold 251–252
 - DNA hypermethylation 249
 - DPP-4 inhibitors 141–142
 - drug discovery 3–36, 54, 58, 66–71, 89, 156, 170, 224–225, 285
 - from academic groups 3
 - drug metabolism and pharmacokinetics (DMPK) optimization strategy 62, 256, 267

druggable proteome 58–59

dulaglutide 93, 95, 98–99

e

efpeglenatide 94–95

emicizumab (HEMLIBRA)

activated prothrombin complex

concentrate (aPCC) 224

anti-FVIII neutralizing

alloantibodies 224

application of technology 233

asymmetric bispecific IgG

antibody 225–226

bleeding prophylactic treatment

223

clinical pharmacology

investigations

bioavailability study 238–239

model-informed phase III dose

selection 237–238

common light chain, of

asymmetric bispecific IgG

antibody 232

extended half-life (EHL) FVIII

products 224

gene encoding FVIII 223

homodimerized antibodies 233

identification of clinical candidate

226–229

in vivo characteristics of

230–231

late-phase clinical development

non-interventional study 239

phase III studies 239–242

mechanism of action and *in vitro*

characteristics 229–230

phase I and I/II studies

multiple ascending dose studies

236

single ascending dose studies

235–236

recombinant FVIIa (rFVIIa)

product 224

empagliflozin 111, 113, 119–125,

138–143

endogenous T cell receptors (TCRs)

161–166, 169

enzymatic assay system 230

enzyme-linked immunosorbent

assay (ELISA) 279

epothilones 17–18

epoxomicin 21–23

eptinezumab 208–210

equilibrium dialysis method 256

erenumab 202, 208, 210

eribulin 18–20

erythema nodosum leprosum 50

p-ethylbenzoyl chloride 127

4-ethylphenyl magnesium bromide

127

eukaryotic cell cycle 274

event-driven pharmacology

61–62, 66

Ex4 based analogues

efpeglenatide 94–95

exenatide 92–94

exenatide long-acting release

(LAR) 94

lixisenatide 94

pegylated dloxenatide 95

exenatide 92–95

exenatide long-acting release (LAR)

94

exendin-4 90

extracellular domain (ECD)

91–92, 102, 163

extracellular scFV 166

f

Fab sequences 227
 fluorescence-activated cell sorting
 (FACS) analysis 281
 2-(4-fluorophenyl)-5-(5-iodo-2-methylbenzyl)thiophene
 132
 4-fluorophenylthiophene 133
 5-fluoropyridin-3-amine 261
 β -fragmentation 119
 fremanezumab 202, 208, 210, 211
 Friedel–Crafts acylation of
 phenetole (PhOEt) 116
 Friedel–Crafts reaction 119, 125,
 133
 FVIII-deficient plasma 227, 230,
 234, 235

g

G protein-coupled receptor,
 calcitonin receptor-like
 receptor (CALCRL) 199
 GABA receptor agonists 8
 GABA uptake inhibitors 8
 galcanezumab 208, 210, 211
 γ -aminobutyric acid
 aminotransferase (GABA-AT)
 8
 glioblastoma U87 cells 254
 GLP-1 receptor agonists
 cardiovascular protective effects
 90
 cryo EM structure 91
 discovery and compounds 93
 exendin-4 90
 GLP-1 based analogues
 albiglutide and albenatide 100
 co-agonists 99–100
 dulaglutide 98–99
 liraglutide 95–96

 semaglutide 96–97
 taspoglutide 97–98
 incretins 89
 peptide sequence 90, 163
 T2DM and obesity treatment
 dipeptidyl peptidase-IV
 (DPP-IV) 90–91
 Ex4 based analogues 92–94
 pharmaceutical developments
 92
 receptor binding and activation
 91–92
 Glucagon 89–92, 100–102
 D-gluconolactone 116, 119, 123,
 125, 127, 130
 glucose tolerance test 102
 L-glutamic acid decarboxylase
 (GAD) 8–10
 C-glycoside 111, 117
 O-glucosides 111, 113–114, 133,
 137
 glycine carbamate 258
 glycosyl cross-coupling 117, 121
 Gramicidin S 11, 12

h

β -hairpin 68
 hemophilia A plasma 234
 heterocyclic replacements 280
 high throughput screening (HTS)
 campaign 3, 250, 252, 267,
 276–278
 histone deacetylase inhibitors
 27–29
 homodimerized antibodies 232,
 233
 hook effect 61
 Huisgen 1,3-dipolar cycloaddition
 reaction 57
 Huisgen reaction 57

- human leukocyte antigens (HLA)
 - 160, 164–165
- human pregnane X receptor (hPXR)
 - 259–261
- hydrochloride salt 6
- hydrophobic binding site 58, 59, 92
- hypoxia-inducible factor-1 α (HIF-1 α) 49–50, 55

i

- Immune suppressive tumor
 - microenvironment (TME) 180
- immunomodulatory drugs (IMiDs)
 - 50, 54, 64, 66–68, 70
- incretin effect 89
- incretins 89
- indisulam 68
- 3-indole 254
- Institute for Clinical Economic Review (ICER) 208
- insulin 23–25, 89, 90, 94, 96, 100, 111, 113, 140, 142–145
- interleukin-6 (IL-6) 174–175
- in vitro-in vivo* correlations (IVIVC) 62
- 5-iodo-2-methylbenzoic acid 133
- iodonium triflate 123
- ion chromatography analysis 232
- ipragliflozin 111, 125, 129–131, 136–138, 141, 143–144
- (S)-3-isobutyl-GABA 9
- isocitrate 249–250
- isocyanide 260–261
- isopropylidene hydrolysis 124
- isopropylmagnesium chloride 132
- ivosidenib
 - AG-120
 - discovery of 257–260

- preclinical characterization of
 - 261–262
- synthesis of 260–261
- clinical studies 262
- crystal structure of 250
- implication 249
- mIDH1 Inhibitors 250–252
- structural analysis 251

j

- JeKo-1 mantle cell lymphoma cell
 - line 279, 281
- Jeko-1 mantle cell lymphoma
 - subcutaneous xenograft model 281

k

- Kisqali® (ribociclib)
 - cross-screening 277–282
 - cyclin D1-CDK4 281
 - disease background 273–274
 - drug discovery efforts 276
 - early phase clinical studies 283–284
 - fragment-based approach 276–277
 - phase 3 clinical studies 284–285
 - target background and validation 274–276

l

- lead peptide 102
- lenalidomide 5, 23, 50, 54, 55, 64, 67
- lentiviral vector-engineered T cell
 - products 177
- licogliflozin 113, 115, 141
- ligandable proteome 71
- β -ligation 116
- liraglutide 95–96, 99

lixisenatide 94

luseogliflozin 123

m

major histocompatibility complex
(MHC) class 164

market capitalization 3

4-methoxy-2-methylbenzoic acid
124–125

2-methoxypropene 127

4-methyl GABA 9

methylaminophenyl analogs 254

N-methylmorpholine 119

methylsulfanyl(tributyl)stannane
119

5'-methylsulfanyl derivative 119

mode of action (MoA) 22, 59–61,
66, 224, 267

monoclonal antibodies 25–26,
200, 202, 208, 210, 212, 236

monovalent degraders 47, 64–71

multiple myeloma 6, 23, 48, 50,
67, 187

mustard gas 6, 7

myelosuppression 282

n

N-terminus 100, 254

new drug applications (NDAs)
197, 207

nitrogen-linked analogs 254

no observable adverse effect level
(NOAEL) 231, 234

o

olcegepant 201, 204, 205

overall response rate (ORR) 185,
186, 265

(*S*)-5-oxopyrrolidine-2-carboxylic
acid 261

p

Pacific Yew Act 16

paclitaxel 14–17

palladium hydroxide 125, 128

parallel artificial membrane
permeability assay (PAMPA)
279

patent lifetime 4

Pd-mediated coupling 261

pegylatedloxenatide 95

peracetyl glucosylated
benzophenone 119

persilylated *D*-gluconolactone 116,
119

pharmacokinetics (PK) 62, 121,
170, 227, 236, 240

pharmacometric approach 238

phlorizin 113, 115

polar surface area (PSA) 50, 62,
260

poly-ubiquitination 48, 49

pomalidomide 5, 50, 54–56, 67

pregabalin 8–10

proteasome inhibitors 22, 48

protein destabilizers 66

protein-coding genes 58

Proteolix 23

publicly funded organizations 3,
4

4-pyridyl 254

pyrrole 276

pyrrolopyrimidinone 277

r

radiation therapy 6

rapamycin 64, 65

remogliflozin 111, 113, 133–137,
142

ribociclib 273, 277, 279–285

rimegepant 204, 205, 207, 208

rituximab 5, 25–26

rizatriptan 207

S

selective estrogen receptor degrader
(SERD) 66

semaglutide 96–98

sitagliptin 91, 135, 142

sodium-glucose linked transporter 2
(SGLT2) inhibitors

empagliflozin 113

gliflozin inhibitors

bexagliflozin 122–123

canagliflozin 130–133

dapagliflozin 114–118

ertugliflozin 128–129

ipragliflozin 129–130

luseogliflozin 123–125

remogliflozin 133–134

sotagliflozin 119

tofogliflozin 125–128

mechanism of action 112–113

natural glucose reabsorption
threshold 112

safety profile and adverse events
141–143

type 2 diabetes treatment

application 143–144

bodyweight reduction
140–141

cardioprotective effects 138

randomized controlled trials
136

renoprotective potential patient
139

sotagliflozin 111, 114, 119–121,
143, 144

O-spiroketal ring system 125

STELLA-LONG TERM trial 143

streptomycin 11

structural Genomix consortium 29

structure activity relationship (SAR)

17, 19, 20, 32, 115, 250, 252,

254, 255, 257, 260, 267, 278

suberoylanilidehydroxamic acid

(SAHA) 27–29

sulfonylureas 113, 140

sumatriptan 201, 208

sunitinib 32, 33

T

T cell receptor (TCR) 161–166
antigen presenting cells (APCs)
164

challenges with 165

clinical trials 162

complementary-determining
regions (CDRs) 163

costimulatory receptors 163

extracellular domains 163
Human Leukocyte Antigens
(HLA) 164

maturation process 162–163

T cell redirecting antibodies 233

targeted protein degradation 47,
48, 51, 53, 54, 57–60, 71

accumulation 59

amide-bond formation 57

binary vs. ternary complex
formation approaches 66

catalytic mode of action 60–61

cellular retinoic acid-binding
proteins (CRABP-I and-II)
49

CRBN ligands 55

cytosolic 50

design and optimization 55

- disadvantages and limitations 62–64
- druggable proteome 58–59
- E3 ligase cereblon 49
- E3 ubiquitin ligase 48
- event-driven pharmacology and prolonged PD effect 61
- historical development 49
- Huisgen 1,3-dipolar cycloaddition reaction 57
- MDM2 ligands 55
- MetAP2 protein 49
- molecular glue-like degraders and monovalent degraders
 - conventional binary approaches 66
 - CRBN degron-containing proteins 70
 - CRBN neo-substrates 68
 - event-driven pharmacology 66
 - FRB domain 65
 - immunomodulatory drugs (IMiDs) 66
 - mode of action (MoA) 66
 - phenotypic screening approach 67
 - protein destabilizers 66
 - thalidomide analogs 68
- of neo-substrates 50
- peptidic binding ligands 49
- scaffolding functions 59–60
- target specificity 60
- ubiquitin-proteasome system (UPS) 48
- ubiquitin-proteasome system and E3 ligases
 - bivalent degrader approach 54
 - CRBN expression 54
 - heterobifunctional molecules 55
 - heterogeneous substrate specificities 53
 - Ikaros and Aiolos 54
 - K48 ubiquitin chains 53
 - of lenalidomide and pomalidomide 54
 - RING E3s, HECT E3s and RBR E3s 53
 - tissue-or compartment-specific expression 54
 - VHL ligands 55
- taspoglutide 97–98
- Taxol 14–18
- telcagepant 201, 202, 204, 205, 207, 210
- tenofovir 30, 31
- 1,1,3,3-tetramethyldisiloxane 133
- 2,3,4,6-tetra-*O*-trimethylsilyl- β -D-gluconolactone 133
- thalidomide 5–6, 49, 67
- thiazole 254
- thiazolidinediones 113
- C*-thioglucosides 123
- tocilizumab 185
- tofogliflozin 111, 125–129, 136–138, 141, 142
- transmembrane domain (TMD) 59, 91, 92, 102, 103, 163, 166–168
- triethylsilane 116, 117, 120, 121, 125, 127, 131, 132
- trimethylsilyl deprotection 121–122
- trimethylsilyl triflate 119, 123
- Truvada™ 30, 31
- tumor 2-HG inhibition 256–259
- tumor infiltrating lymphocytes 160

u

- ubiquitin-proteasome system (UPS)
 - 48, 53–55, 63, 73
- ubiquitination 48–50, 53, 57, 60,
 - 62, 68, 70
- Ubrogapant 204, 205, 207, 208
- Ugi four-component reaction 261
- Ugi reaction 251–253, 256, 263,
 - 267, 273
- L-uronic acid 119

v

- VERTIS MET trial 136, 140, 142
- VHL-1 50, 51, 56

